{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T05:27:43Z","timestamp":1671859663378},"reference-count":21,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1628,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1111\/j.1365-2710.2011.01254.x","type":"journal-article","created":{"date-parts":[[2011,3,18]],"date-time":"2011-03-18T06:30:36Z","timestamp":1300429836000},"page":"336-341","source":"Crossref","is-referenced-by-count":7,"title":["Managing statin-induced muscle toxicity in a lipid clinic"],"prefix":"10.1155","volume":"36","author":[{"given":"O.","family":"Blaier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lishner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Elis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2011,3,18]]},"reference":[{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ahj.2003.12.037","article-title":"Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors","volume":"147","author":"Jamal","year":"2004","journal-title":"American Heart Journal"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3949\/ccjm.72.11.990","article-title":"Safety of statins: effect on muscle and liver","volume":"72","author":"Abu","year":"2005","journal-title":"Cleveland Clinic Journal of Medicine"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2710.2011.01254.x-BIB4|cit4","first-page":"III50","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"Journal of the American Medical Association"},{"issue":"Suppl. 8A","key":"10.1111\/j.1365-2710.2011.01254.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","article-title":"An assessment of statin safety by muscle experts","volume":"97","author":"Thompson","year":"2006","journal-title":"American Journal of Cardiology"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1345\/aph.10228","article-title":"Rhabdomyolysis and HMG-CoA reductase inhibitors","volume":"35","author":"Omar","year":"2001","journal-title":"Annals of Pharmacotherapy"},{"issue":"Suppl. 8A","key":"10.1111\/j.1365-2710.2011.01254.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data - 2005","volume":"97","author":"Bays","year":"2006","journal-title":"The American Journal of Cardiology"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.5694\/j.1326-5377.2001.tb143683.x","article-title":"Statin-associated myopathy","volume":"175","author":"Hamilton-Craig","year":"2001","journal-title":"The Medical Journal of Australia"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","article-title":"Current overview of statin-induced myopathy","volume":"116","author":"Rosenson","year":"2004","journal-title":"American Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001648-200109000-00017","article-title":"Lipid-lowering drugs and risk for myopathy: a population-based follow-up study","volume":"12","author":"Gaist","year":"2001","journal-title":"Epidemiology"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"23K","DOI":"10.1016\/S0002-9149(03)00779-3","article-title":"Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams","volume":"92","author":"Brewer","year":"2003","journal-title":"American Journal of Cardiology"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB15|cit15","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"The 4S study group","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1016\/0002-9343(91)90053-Z","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin","volume":"91","author":"Dujovne","year":"1991","journal-title":"American Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\\TexCAPS (Air Force\/Texas Coronary Atherosclerosis Prevention Study)","volume":"279","author":"Downs","year":"1998","journal-title":"Journal of the American Medical Association"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0002-9149(01)01464-3","article-title":"Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS): additional perspectives on tolerability of long-term treatment with lovastatin","volume":"87","author":"Downs","year":"2001","journal-title":"American Journal of Cardiology"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80\u2003mg, ezetimibe alone, and the combination of fluvastatin XL 80\u2003mg with ezetimibe in patients with a history of muscle-related side effects with other statins","volume":"101","author":"Stein","year":"2008","journal-title":"American Journal of Cardiology"},{"key":"10.1111\/j.1365-2710.2011.01254.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen","year":"2005","journal-title":"Archives of Internal Medicine"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2011.01254.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2011.01254.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:46Z","timestamp":1671818626000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2011.01254.x"}},"subtitle":["<i>Managing statin-induced muscle toxicity<\/i>"],"short-title":[],"issued":{"date-parts":[[2011,3,18]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2011.01254.x","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,18]]}}}